Octapharma Plasma GmbH, Langenfeld, Germany.
Transfus Apher Sci. 2023 Apr;62(2):103680. doi: 10.1016/j.transci.2023.103680. Epub 2023 Feb 24.
Convalescent plasma has been used for a long time for the treatment of various infectious diseases. The principle is to collect antibody-containing plasma from recovered patients and to transfuse the plasma to infectious patients thereby modifying their immune system. This approach was also used in the SARS-CoV-2 pandemic when no specific drugs were available for the treatment of the disease.
This short narrative review reports on relevant studies of collection and transfusion of Covid-19 convalescent plasma (CCP) from 2020 until August 2022. Clinical patients' outcome parameters such as need for ventilation, length of hospital stay and mortality were analysed.
Heterogenous patient groups were studied resulting in difficult comparability of the studies. High titer of transfused neutralizing antibodies, early onset of CCP treatment and moderate disease activity were identified as key parameters for effective treatment. Special subgroups of patients were identified to benefit from CCP treatment. No relevant side effects were observed during and after collection and transfusion of CCP.
Transfusion of CCP plasma is an option for the treatment of special subgroups of patients suffering from SARS-CoV-2 infection. CCP can be easily used in low-to-middle income countries where no specific drugs are available for treatment of the disease. Further clinical trials are necessary to define the role of CCP in the treatment of SARS-CoV-2 disease.
恢复期血浆在治疗各种传染病方面已经使用了很长时间。其原理是从康复患者中收集含有抗体的血浆，并将血浆输给感染患者，从而改变他们的免疫系统。在没有针对该疾病的特定药物可用时，这种方法也用于 SARS-CoV-2 大流行期间。
本短篇叙述性综述报告了 2020 年至 2022 年 8 月期间收集和输注新冠病毒（Covid-19）恢复期血浆（CCP）的相关研究。分析了临床患者的预后参数，如需要通气、住院时间和死亡率。
研究对象为异质性患者群体，导致研究结果难以比较。高滴度的输注中和抗体、早期开始 CCP 治疗和中度疾病活动被确定为有效治疗的关键参数。确定了特殊亚组患者可从 CCP 治疗中获益。在收集和输注 CCP 期间及之后未观察到相关副作用。
输注 CCP 血浆是治疗 SARS-CoV-2 感染特殊亚组患者的一种选择。CCP 可在低中等收入国家中轻易使用，这些国家没有针对该疾病的特定药物。有必要进行进一步的临床试验，以确定 CCP 在治疗 SARS-CoV-2 疾病中的作用。
